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Depression is one of the most frequent and severe mental disorder. Since the discovery
of antidepressant (AD) properties of the imipramine and then after of other tricyclic
compounds, several classes of psychotropic drugs have shown be effective in treating
major depressive disorder (MDD). However, there is a wide range of variability in response
to ADs that might lead to non response or partial response or in increased rate of relapse
or recurrence. The mechanisms of response to AD therapy are poorly understood, and few
biomarkers are available than can predict response to pharmacotherapy. Here, we will first
reviewmarkers that can be used to predict response to pharmacotherapy, such as markers
of drug metabolism or blood-brain barrier (BBB) function, the activity of specific brain areas
or neurotransmitter systems, hormonal dysregulations or plasticity, and related molecular
targets. We will describe both clinical and preclinical studies and describe factors that
might affect the expression of these markers, including environmental or genetic factors
and comorbidities. This information will permit us to suggest practical recommendations
and innovative treatment strategies to improve therapeutic outcomes.
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INTRODUCTION
Major depressive disorder (MDD) is among the most frequent
mental disorders, with an estimated lifetime prevalence of 1–16%,
depending on the country (Andrade et al., 2003; Kessler and
Ustun, 2004; Kessler et al., 2010). Recovering from MDD is
a major challenge because the disease dramatically increases
the risk of suicide (Cheng et al., 2000) and non-suicide mor-
tality (Schulz et al., 2002). Practical guidelines recommend
treating MDD with antidepressant (AD) therapy (NICE, 2004;
Bauer et al., 2007; Ramasubbu et al., 2012). Since the initial
serendipitous discovery of the AD effect of monoamine oxi-
dase inhibitors (MAOIs) and tricyclics (TCAs), most ADs have
been pharmacological agents that act on monoamine func-
tion, including serotonin (selective serotonin reuptake inhibitors,
SSRIs), noradrenaline (noradrenaline reuptake inhibitors, NRIs),
dopamine (such as bupropion), and melatonin (agomelatine).
Some drugs act on several of these targets (serotonin and nora-
drenaline reuptake inhibitors, SNRIs) (Krishnan and Nestler,
2008). The main goals of treating MDD are to achieve remis-
sion and to maintain these therapeutic effects over time. In
the absence of any reliable biomarker of MDD, the response to
treatment is still based on clinical assessment as evidenced by
changes on scores on standardized rating instruments, such as the
Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960) or
the Montgomery Asberg Depression Rating Scale (Montgomery
and Asberg, 1979). The response to ADs is typically character-
ized as “non-response” when only minimum improvement is
achieved, “partial response” when the score on the standardized
instrument decreases by 25–50%, “response” when a decrease
of at least 50% is obtained, and “remission” when only residual
clinical symptoms are reported, with a level of psychopathology
under the typical threshold score currently correlated to MDD
diagnosis (Nierenberg and DeCecco, 2001). Using these crite-
ria, several studies, including the naturalistic STAR∗D study, have
shown that only one third ofMDD patients receiving ADs achieve
complete remission after a single AD trial (Trivedi et al., 2006).
The remission rate reaches up to 60% after four trials, but the
probability of remission drops significantly after the failure of
two consecutive AD trials (Rush et al., 2006). Moreover, early
improvement predicts sustained response and remission (Lam,
2012). Consequently, the concept of treatment-resistant depres-
sion (TRD) was proposed to describe depressive conditions that
did not reach sufficient remission after treatment (Lehmann,
1974; Sartorius, 1974). Even several criteria have been proposed
to define TRD-including non-response to one AD for at least 4
weeks or failure to respond to multiple trials of different classes
of ADs-there is now an emerging consensus to consider any
MDD patient that did not respond to two or more adequate (in
terms of duration and dosage) AD trials of different classes as
TRD (Berlim and Turecki, 2007). The characterization of TRD
has been improved by considering the level of resistance (sever-
ity and duration) through staging classifications, such as the
Antidepressant Treatment History Form (ATHF) (Sackeim et al.,
1990), the Thase and Rush Model (Thase and Rush, 1997), the
European Staging Model (Souery et al., 1999), the Massachusetts
General Hospital Staging Model (MGH-s) (Fava, 2003), and the
Maudsley Staging Model (MSM) (Fekadu et al., 2009) (for a
review, see Ruhé et al., 2012).
Translational research enables to study the mechanisms of non
response to ADs in animal models. Indeed, this involves invasive
protocols, as particular proteins, brain areas or process have to
be suppressed to elucidate their causal involvement in response
to AD. Therefore, bioassays (forced swim test, tail suspension
tests. . .) and more generally animal models have been designed
www.frontiersin.org November 2013 | Volume 4 | Article 146 | 1
El-Hage et al. Predictors of antidepressant response
that enable to induce a behavioral deficit after experimental
manipulations (stressors during the developmental period, social
defeat or unpredictable chronic stress during adulthood, chronic
corticosterone). The induced modifications are then assessed via
behavioral testing such as scoring of sucrose preference, of coat
state, of grooming behavior, of anxiety-related behavior. It is usu-
ally observed that chronic ADs reverse the behavioral alterations
that have been induced by the experimental manipulations and
this enables to assess AD response (depending on the magnitude
of the reversal that has been observed, and on the number of
behavioral dimensions that have been counteracted). It is pivotal
here to assess several different behaviors, as it can succeed that
only a specific phenotype is reversed, and not the others as seen
for example in David et al. (2009).
The main aim of this paper is to review the different poten-
tial predictors of response/non response to AD and discuss their
clinical and practical implications. We will successively discuss
the potential mechanisms and correlates of response to ADs with
regard to some general clinical and pharmacological considera-
tions and at the different levels of neurobiological understanding
of AD mechanisms of action (Kupfer et al., 2012), with a par-
ticular consideration of the neuroanatomical, neurotransmission,
molecular, and genetic levels, as well as to potential hormonal and
neuroplasticity aspects (Table 1).
POOR RESPONSE TO ANTIDEPRESSANT THERAPY:
CLINICAL CORRELATES
The efficacy of ADs has been strongly debated recently because
of negative randomized controlled studies in which the response
rates in the placebo control group were as high as 30–40%
(Iovieno and Papakostas, 2012). Rather than arguing against the
efficacy of ADs in MDD, these results indicated some method-
ological limitations of studies recently submitted to the European
or US authorities (Khin et al., 2011). In particular, an inappropri-
ately low baseline disease severity is likely the most problematic
methodological flaw that eliminates the statistical significance of
the difference in the response rate between the active and placebo
groups (Kirsch et al., 2008; Fournier et al., 2010).
Another important methodological consideration is that even
if the rating scales (such as the HDRS) on which the treatment
response is assessed are robust and reliable, not all items of the
scale (e.g., anxiety, somatic, early insomnia, hypochondriasis, and
somatic symptoms) represent equal proportions of the observed
change in the global score (Nelson et al., 2005). This could explain
why a high level of anxiety symptoms could result in an underesti-
mation of the response to treatment and why anxiety disorders are
frequently associated with TRD (Souery et al., 2007). Other clini-
cal characteristics are associated with a higher risk of low response
to ADs. In particular, some MDD patients who meet the criteria
for TRD are later revealed to suffer from bipolar disorder (Fekadu
et al., 2012). Bipolar depression is less prone to respond to ADs
than MDD (Gijsman et al., 2004), even though recent findings
suggest that ADs may be as effective against bipolar depression as
against MDD (Tondo et al., 2013; Vázquez et al., 2013).
Among clinical characteristics, older age has also been shown
to be associated with a lower response rate to ADs. In a meta-
analysis conducted on 15 late life MMD trials and 59 adult MDD
trials, it was found that the response rate drops from 53.9% in
Table 1 | Mechanisms predicting response to antidepressants.
Main predictors of poor response to antidepressant treatment
CLINICAL CORRELATES
• Bipolar depression
• Older age in relation to age or somatic
comorbidities (cardiac, cerebrovascular,
neurodegenerative disorders)
• Poor compliance to antidepressants in relation
to low income, health insurance status,
race/ethnicity
PHARMACOLOGICAL CORRELATES
Drug metabolism • Younger age, sex, smoking status, pregnancy,
drug dose, diet, grapefruit, genetics, enzyme
induction/inhibition
• Ultra-rapid metabolizers in relation to hepatic
metabolism: genetic differences in
drug-metabolizing enzymes (cytochromes
P450; e.g. CYP2D62, CYP2C19)
• Alteration of hepatic, renal or cardiovascular
functions
• Polypharmacy enhances drug interactions,
particularly fluvoxamine, fluoxetine, paroxetine,
nefazodone
Blood-brain barrier • Polymorphisms in genes coding for ABC
transporter proteins, particularly the
P-glycoprotein (P-gp)
• Drugs that are substrates of P-gp have
decreased penetration into the brain
NEUROBIOLOGICAL CORRELATES
Brain structures EEG (alpha and theta activities)
• Lower alpha rhythmic activity in posterior
regions (among amitriptyline non-responders)
and in left hemisphere (SSRIs)
• Higher theta rhythmic activity among
imipramine non-responders
• Decreased pre-treatment theta activity in the
ACC
Neuroimaging (fMRI, PET)
• Lower baseline rostral ACC activity
• Low ACC activity during functional tasks
• Reduction in frontolimbic gray matter volumes
(medial and orbital PFC)
• Smaller baseline hippocampal volume
• Abnormalities in corticolimbic connectivity
• Higher right- over left hemisphere processing
• Higher baseline metabolism in the amygdala
and thalamus, and lower pretreatment
metabolism in the medial PFC
• Insula hypometabolism
Neurotransmission Serotoninergic system
• Alteration of the 5-HT1A pre- and postsynaptic
receptors dynamic
• Polymorphism of the 5-HT transporter gene
(short allele carriers)
• SNPs of tryptophan hydroxylase genes (TPH1
and TPH2)
(Continued)
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Table 1 | Continued
Main predictors of poor response to antidepressant treatment
• SNPs of the 5-HT1A receptor gene (1019C/G;
102T/C; 1438A/G)
• Interaction between stressful life events and
polymorphisms in 5-HT related genes
Noradrenergic system
• Alteration of the dopamine beta-hydroxylase
enzyme/gene
• Deficiency in organic cation transporter 2
• Polymorphisms of the noradrenaline
transporter gene (-182T/C; 1287G/A)
• Polymorphism of the
catechol-O-methyltransferase gene (Val
homozygous)
• Early life stress events (via gene methylation or
acetylation)
Other systems
• Decreased substance P in the cerebrospinal
fluid
• SNPs of the dystrobrevin-binding protein 1
gene (glutamatergic neurotransmission)
• SNPs of the glutamate receptor ionotropic
kainite 4 gene (rs1954787; rs12800734)
• Deletion of the gene encoding the GABA
transporter subtype 1
• Genetic variability in endocannabinoid
receptors (CNR1; G allele of rs1049353 in
females)
• Deficit in the leptin system (decreased leptin
serum levels, reduced leptin mRNA
expression)
Neural plasticity Molecular aspects
• Polymorphism in the BDNF gene (Val allele
carriers)
• Alteration of BDNF in the dentate gyrus
(hippocampus)
• Alteration of protein p11, mediating the
antidepressant activity of BDNF
• Interaction between ongoing stress and the
levels of BDNF
• Zinc deficiency
• Macrophage migration inhibitory factor
deficiency
Cellular targets
• Alteration in adult hippocampal neurogenesis
• Alteration of the generation of new functional
neurons
Hormonal targets HPA axis
• Defect in the HPA axis regulation (defect in
normalization of its overactivity)
• No reduction of the cortisol response to a
dexamethasone/CRH test after 2–3 weeks of
treatment
• Polymorphisms of genes coding for FKBP5,
BclI, ER22/23EK, CRHR1 (rs242941), CRHR2
(rs2270007), CRH-BP, and hsp70 protein
(Continued)
Table 1 | Continued
Main predictors of poor response to antidepressant treatment
• Somatic condition: Cushing’s disease
• Interaction between stressors and genes
(SERT, FKBP5, CRHR1) to predict response to
treatment
Thyrotropin releasing hormone
• Hypothyroidism; Polymorphism of the
deiodinase type 1 gene
ACC, Anterior cingulate cortex; BclI, ER22/23EK, Polymorphisms of glucocorti-
coid receptor gene; BDNF, Brain-derived neurotrophic factor; CRH, Corticotropin-
releasing hormone; CRHR-BP, CRH binding protein; CRHR1, CRH receptor 1;
CRHR2, CRH receptor 2; EEG, Electroencephalography; FKBP5, FK506 binding
protein 5; fMRI, Functional magnetic resonance imaging; HPA, Hypothalamic-
pituitary-adrenal; PET, Positron emission tomography; PFC, Prefrontal cortex;
SERT, serotonin transporter; SNPs, Single-nucleotide polymorphisms; SSRIs,
Selective serotonin reuptake inhibitors; 5-HT, Serotonin.
adults to 45.2% in older patients (Tedeschini et al., 2011). In
adolescents, response rate has been shown to be much higher,
several studies reporting response rate at week 36 from 65 (Tao
et al., 2009) to 80% (March et al., 2006), with a mean remis-
sion rate of 67% (Cox et al., 2012). Whether age itself may
explain the difference remains unclear because somatic comor-
bidities may have a role in increasing the risk of non-response
or partial response to ADs in older patients, particularly cardiac
(Scherrer et al., 2012), cerebrovascular (Miller et al., 2002), and
neurodegenerative disorders (Price et al., 2011).
Sex also constitutes a clinical characteristic associated with dif-
ference in AD treatment response. Indeed, a study suggested that
men respond more favorably to imipramine than women, and
premenopausal womenmore frequently to fluvoxamine thanmen
(Vermeiden et al., 2010). In animal studies, Goel et al. (2011)
showed that acute citalopram induced higher neuronal activa-
tion in male brain than in females or gonadectomized males.
This suggests a gonadal hormone influence on complex interac-
tions between serotonin and neural circuits that mediate the stress
axis (see section HPA Axis Regulation below) and could therefore
explain some of the sex differences in the response to AD.
The lack of response to ADs may also be the consequence
of non-adherence to the treatment as the rate of adherence to
ADs has been estimated to be particularly low, varying over
a period of six months from 12.4% for patients taking older
MAOIs and TCAs to 29.3% for those taking SSRIs and 33.6% for
those taking SNRIs (Sheehan et al., 2008). In a 9-week follow-
up period, up to 20% of patients missed taking their treatment
for at least four consecutive days (Demyttenaere et al., 2001).
This poor compliance has been shown to alter the estimation of
response and remission rates (Akerblad et al., 2006). According
to Jin et al. (2008), various factors contribute to non-compliance.
Jeon-Slaughter (2012) found that low income level, combined
with health insurance status and race/ethnicity, predicted non-
adherence to ADs. This was confirmed in a recent review (Rivero-
Santana et al., 2013) that demonstrated that younger people were
less compliant than older patients and minority ethnic patients
were less compliant than white patients. Non-pharmacological
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interventions can improve the adherence to AD treatments.
Vergouwen et al. (2003) found that collaborative interventions
in primary care were associated with clinical benefit, particularly
in patients suffering from MDD who were prescribed adequate
dosages of ADs.
PREDICTORS OF POOR RESPONSE TO ANTIDEPRESSANT
THERAPY: PHARMACOLOGICAL COMPONENT
DRUG METABOLISM
Availability of the drug to its brain targets is one of the first
requisite conditions of its effect and clinical impact. However,
various conditions affect drug delivery such as its metabolism.
Drug metabolism is altered by a wide range of factors such as
age, rate of expression of drug metabolism systems, comorbid
disease, sex, pregnancy, environment, drug dose, enzyme induc-
tion/inhibition, diet, genetics. . . For instance, younger people
metabolize drugs faster than elderly people, men faster than
women, and smokers faster than non-smokers. AD medications
are metabolized mainly in the liver into compounds that are
typically pharmacologically active but with different properties
than the parent drug. Drug metabolism may result in poor
response. Hepatic metabolism mainly occurs via cytochrome
P450 (CYP) enzymes, which comprise more than 200 isoen-
zymes (mainly CYP1A2, CYP2B6, CYP2D6, CYP2C9, CYP2C19,
and CYP3A4/5): they account for 75% of drug metabolism
(Guengerich, 2008), particularly oxidative metabolism.
Variations in CYP genes have been shown to be associated
with modified pharmacokinetic clearance of ADs. In humans,
CYP is encoded by 18 families and 43 subfamilies of genes, cor-
responding to 57 genes and more than 59 pseudogenes. Thus,
many different genes may alter CYP, some patients being poor
and others ultrarapid metabolizers. When ultrarapid metaboliz-
ers are treated with typical doses of ADs, they have low plasma
concentrations and do not respond. Polymorphisms in genes for
crucial CYP enzymes, such as CYP2D6 or CYP2C19, alter the
metabolism of ADs and thus their plasma concentrations (Brosen,
2004). Carriers of the non-functional allele of CYP2C19 exhibit
a 42% decrease in clearance of the SSRI citalopram compared
to carriers of the functional allele (Yin et al., 2006). Bondolfi
et al. (1996) investigated seven non-responders to citalopram; six
were extensive CYP2D6 metabolizers, and all seven were exten-
sive CYP2C19 metabolizers. Furthermore, when administered an
inhibitor of these two enzymes, citalopram serum levels rose in all
subjects, as well as the therapeutic response. However, Grasmäder
et al. (2004) found that plasma concentrations of several ADs
were altered depending on the CYP2D6 and CYP2C19 geno-
type, even if this genotype was unrelated to clinical response.
Peters et al. (2008) using subjects from the STAR∗D study found
no association between 15 polymorphisms of four P450 genes
(CYP2D6, CYP2C19, CYP3A4, and CYP3A5) and citalopram
response. More recently, Mrazek et al. (2011) examined data
from the white non-Hispanic subjects who were treated with
citalopram in the same STAR∗D sample. They found a modest
association between CYP2C19 variation and remission following
citalopram, particularly in a subset of patients able to tolerate the
medication. Thus, evidence on the association between genetic
variations in CYP and AD response is inconsistent and likely
depends on the patients and drug used.
Among the environmental factors that influence pharmacoki-
netics, smoking, treatment adherence, and concurrent medi-
cations are particularly important. There are numerous drug
interactions with cigarette smoking. Suzuki et al. (2011) found
that smoking status significantly affected fluvoxamine concentra-
tion (only in the low 50mg/d dose group). Together, CYP2D6
genotype and smoking status explained 23% of the variance in
fluvoxamine concentration in this group.
Failure to respond to or tolerate a drug may be related to
comorbid medical conditions (hepatic or renal insufficiency,
cardiovascular disease) and/or to its related polypharmacy.
Comorbid medical conditions that alter hepatic function are
likely to decrease the rate of drug metabolism. In addition, co-
prescriptions increase the risk of drug-drug interactions with ADs
in the treatment of comorbid illness. Drug interactions are more
likely to occur with high-risk drugs, such as fluvoxamine, fluox-
etine, paroxetine, and nefazodone (Richelson, 1998). Coelho and
Brum Cde (2009) investigated the interactions between ADs and
antihypertensive and glucose-lowering drugs at two primary care
units and found that 19 of 29 patients were exposed to 47 inter-
actions involving pharmacokinetic and pharmacodynamic mech-
anisms. When initiating a new prescription, the physician should
select an AD while considering comorbid medical conditions,
including dosage adjustment, possible drug interactions, adverse
effects, and tolerability issues. The physician should also inform
the patient about the influence of co-administered drugs and
simultaneous intake of beverages and food on the bioavailabil-
ity of drugs. For instance, grapefruit juice consumption increases
themean peak plasma concentrations and the concentration-time
curve of sertraline (Ueda et al., 2009) and fluvoxamine (Hori
et al., 2003).
In case of TRD, therapeutic drug monitoring is a valuable
tool for tailoring the dosage of the prescribed medication to
the individual characteristics. Dose titration is strongly recom-
mended to achieve therapeutic plasma concentrations that allow
for the highest probability of response or remission. In addi-
tion to drug concentration measurements, symptom rating by
the treating physician at baseline and at week 2 is recommended
(Hiemke et al., 2011). In certain situations, AD monitoring could
be combined with pharmacogenetic metabolism tests (Hiemke
et al., 2011). For instance, when the concentrations are out-
side the reference range, pharmacogenetic tests could be recom-
mended to detect polymorphisms that give rise to slow/rapid
metabolizers. Winner et al. (2013) recently demonstrated that
pharmacogenomic-directed prescribing reduced the incidence of
adverse drug reactions and improved the efficacy of AD medi-
cation regimens. Thus, pharmacogenomic testing to determine
metabolic capacity may be a valuable strategy to recognize indi-
viduals who will obtain a therapeutic benefit from a drug.
BLOOD-BRAIN BARRIER
Among the mechanisms of poor response to ADs, the drug
efflux transporters that are expressed at the blood-brain bar-
rier (BBB) and enable drugs to access the brain play a major
role. The BBB is composed of brain capillary endothelial cells in
association with pericytes and smooth muscle cells that delin-
eate the circulating blood from glial cells and the neuronal
terminals of the central nervous system. The BBB limits the
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traffic of substances to trans-cellular transport rather through
the intercellular spaces because the tight junction system of the
trans-membrane proteins acts as a physical barrier. Consequently,
only lipophilic compounds of low molecular weight are able
to cross the BBB. However, various transport systems ensure
wider exchanges through the BBB, including the ATP-binding
cassette (ABC transporters) system (for lipid-soluble molecules)
(Benarroch, 2012). The human genome encodes 49 different ABC
transporter proteins classified into seven subfamilies (ABCA to
ABCG) (Dean et al., 2001). The P-glycoprotein (P-gp) encoded
by the multi-drug resistance 1 (MDR1/ABCB1) gene, the breast
cancer resistance protein encoded by the ABCG2 gene, and the
multidrug resistance-associated proteins 4 and 5 are expressed
by the brain endothelial cells and ensure active efflux of lipid-
soluble molecules from the brain, reducing penetration of drugs
into the brain. Compounds that interact with ABC transporters
can be classified as substrates, modulators, or inhibitors. AD
drugs interact mainly with P-gp. Thus, ADs that are substrates
of P-gp are subject to greater efflux from brain endothelial cells
and decreased penetration into the brain. Moreover, drug-drug
interactions can also be the consequence of competing/synergic
effects on P-gp. Several drugs, including cyclosporine, nifedip-
ine, quinidine, and verapamil, are P-gp inhibitors (O’Brien et al.,
2012). In vivo preclinical studies, particularly in P-gp knock-
out mice, have demonstrated that not all ADs are subject to
the same level of limitation to brain penetration by P-gp (Uhr
et al., 2000, 2003; Uhr and Grauer, 2003; Karlsson et al., 2013).
Moreover, metabolites of some ADs may not be substrates of
P-gp, in contrast to their parent molecules (Weiss et al., 2003;
Grauer and Uhr, 2004; Wang et al., 2008a). Clinical evidence of
the role of P-gp in the response to ADs has been provided by
studies of variants of the ABCB1 gene. Several single nucleotide
polymorphisms (SNPs) of the ABCB1 gene have been identified
and associated with a decreased clinical response to AD (Kato
et al., 2008; Uhr et al., 2008; Sarginson et al., 2010; Lin et al.,
2011; Singh et al., 2012) as well as a poorer tolerance profile
(Roberts et al., 2002; Jensen et al., 2012; de Klerk et al., 2012),
although several studies failed to replicate these results (Laika
et al., 2006; Mihaljevic Peles et al., 2008; Menu et al., 2010).
Furthermore, endogenous and synthetic glucocorticoids also act
as P-gp substrates (Ueda et al., 1992; Schinkel et al., 1995; Uhr
et al., 2002). Hyperactivity of the hypothalamus-pituitary-adrenal
(HPA) axis is one of the most consistent biological hallmarks of
MDD, and it has been suggested that increased penetration of
glucocorticoids into the brain as a result of P-gp inhibition may
contribute to normalization of HPA axis hyperactivity in MDD
(O’Brien et al., 2012). These data suggest evaluation of P-gp inhi-
bition as an augmentation strategy for improving response to AD
therapy.
PREDICTORS OF POOR RESPONSE TO ANTIDEPRESSANT
THERAPY: NEUROBIOLOGICAL COMPONENTS
Based on the understanding we have of the neurobiological mech-
anisms of action of ADs, the response to ADs can be explored
at the following levels: brain structures, neurotransmission, and
molecular targets.We will now describe each of these mechanisms
(Table 1).
BRAIN STRUCTURES AND RESPONSE TO ANTIDEPRESSANTS
Various studies have explored brain changes associated with
response to ADs by using electroencephalography (EEG) (alpha
and theta activities) or neuroimaging (Functional magnetic reso-
nance imaging: fMRI, Positron emission tomography: PET) that
allow deducing potential mechanisms and markers of response
to ADs.
Brain activity measurements by quantitative EEG in the rest-
ing state or during simple tasks have been used to predict
response to ADs. Ulrich et al. (1986) observed increased alpha
rhythmic activity (8–12Hz) in the posterior regions of the
head on both sides that was higher in amplitude on the domi-
nant side in patients responding to amitriptyline. Subsequently,
Knott et al. (1996) observed higher alpha and less theta rhyth-
mic activity (4–7Hz) among imipramine-responders than non-
responders. Bruder et al. (2001) observed a difference in alpha
asymmetry between fluoxetine responders and non-responders;
non-responders displayed reduced alpha activity over the left
hemisphere than the right, whereas responders tended to have
the opposite asymmetry. Other studies focused on the brain
regions associated with this altered alpha activity. Bruder et al.
(2008) demonstrated that the difference between SSRI responders
and non-responders involved occipital areas, where differences
in alpha asymmetry were also observed. Theta activity was also
investigated. EEG theta frequencies are generated in various brain
areas, such as the medial prefrontal cortex (PFC), anterior cingu-
late cortex (ACC), hippocampus, amygdala, and ventral striatum.
In the ACC, Pizzagalli et al. (2001) found an association between
pre-treatment theta increases in rostral ACC and responses to
nortriptyline. Mulert et al. (2007) reported similar findings with
citalopram or reboxetine. This pre-treatment change in theta
power in relationship to AD outcome has not been consistently
observed (Cook et al., 2002). However, they demonstrated that
the decrease in prefrontal cordance (i.e., the measure of quan-
titative EEG power that characterizes PFC function) that occurs
after 1 week of treatment only in responders is also predictive of
a better final outcome (Cook et al., 2002, 2009). In another study,
Bares et al. (2008) found that reduction in the PFC theta quan-
titative EEG cordance value after the first week of treatment can
predict the response to venlafaxine. Quantitative EEG measure-
ments are now considered a promising clinical tool for predicting
conventional AD treatment response (Leuchter et al., 2009, 2010).
Interestingly, brain electrical activity has also been used to predict
outcomes of non-conventional ADs, such as the NMDA receptor
antagonist ketamine or non-pharmacological AD therapy, such as
deep brain stimulation (DBS). For example, Duncan et al. (2013)
recently demonstrated that measuring sleep slow wave activity
(0.6–4Hz) could predict ketamine response in individuals with
TRD, whereas frontal theta quantitative EEG cordance has been
shown to predict long-term AD response to subcallosal cingulate
DBS in TRD patients (Broadway et al., 2012).
The involvement of the rostral ACC in TRD or treatment non-
response is also supported by neuroimaging studies. Indeed, PET
studies have observed increased baseline rostral ACC activity in
MDD patients who subsequently responded to ADs (Mayberg
et al., 1997; Saxena et al., 2003) while an fMRI study demon-
strated that higher ACC activity during precise tasks, such as
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processing negative stimuli, was associated with the most robust
treatment response (Davidson et al., 2003). Moreover, ACC acti-
vation during unsuccessful motor inhibition predicted response
to escitalopram (Langenecker et al., 2007). Interestingly, a recent
study showed that increased activity in the rostral ACC is a predic-
tor not only of treatment outcome to conventional ADs but also to
putative ADs, such as ketamine (Salvadore et al., 2009), or to non-
pharmacological therapy, such as sleep deprivation (Wu et al.,
1999). Non-response to ADs is correlated with low pre-treatment
activity in the rostral ACC (Mayberg et al., 1997; Pizzagalli,
2011), which is one of the most reliable markers for predict-
ing treatment outcome for conventional monoaminergic-acting
ADs, intravenous ketamine treatment, and non-pharmacological
treatments, such as electroconvulsive therapy (ECT) or repeti-
tive transcranial magnetic stimulation (rTMS) (Pizzagalli, 2011).
However, a low level of activity in the rostral ACC predicts a better
outcome for cognitive behavioral therapy (CBT) (Fu et al., 2008;
Pizzagalli, 2011; Roiser et al., 2012).
Gray matter brain volumes and, more recently, forebrain
white matter integrity have also been measured in patients with
MDD (first episode, remittent, or TRD). Frontolimbic gray mat-
ter areas (medial and orbital PFC) were reduced in the most
severely depressed individuals (i.e., treatment-resistant/chronic
group) (Serra-Blasco et al., 2013). Moreover, patients that did
not respond to escitalopram exhibitedmicrostructural abnormal-
ities in fiber tracts connecting the cortex with limbic structures,
such as the ACC (Alexopoulos et al., 2008). In addition, patients
with TRD displayed abnormalities of both internal and exter-
nal capsule integrity connecting cortical to subcortical nuclei and
of the corpus callosum (Guo et al., 2012). Interestingly, these
corticolimbic pathways are negatively impacted by adverse life
events or by genetic polymorphism of the serotonin transporter
(Alexopoulos et al., 2009; Choi et al., 2009), and corticolimbic
connectivity increased as scores on the HDRS decreased during
treatment (Anand et al., 2005). This suggests that assessing cor-
ticolimbic connectivity could be used to predict AD outcome.
Further, the PFC region is one of the favorite targets for DBS
in patients with TRD (Mayberg et al., 2005; Lozano et al., 2008;
Malone et al., 2009). In addition, Dunkin et al. (2000) reported
pre-treatment difference between fluoxetine responders and non-
responders on PFC-related tasks reflecting executive dysfunction.
Recently, Gupta et al. (2013) demonstrated that patients with
TRD exhibited mildly reduced performance across all neurocog-
nitive domains with a superimposed moderate impairment in
verbal working memory. Finally, Bruder et al. (2004) investigated
dichotic listening and demonstrated that patients who respond to
SSRIs differed from non-responders in favoring left- over right-
hemisphere processing of dichotic stimuli. Fluoxetine responders
displayed greater left-hemisphere advantage for words and less
right-hemisphere advantage for complex tones compared to non-
responders. The cognitive, sensorial, or behavioral alterations
shown in AD responders vs. non-responders are likely related to
differences in the functioning of the brain areas underlying these
functions, and thus, this suggests that brain alterations may also
be valuable predictors of AD outcome.
The ACC is not the sole brain region whose activity can pre-
dict AD response. Indeed, improvement of MDD symptoms after
AD has also been associated with lower pre-treatmentmetabolism
(detected by PET) in the amygdala and thalamus and with higher
pre-treatment metabolism in the medial PFC (Saxena et al.,
2003). The hippocampus has also received some interest, and
a recent study showed that MDD patients who met criteria for
clinical remission at 8 weeks of AD treatment had larger pre-
treatment hippocampal volumes than non-remitters, suggesting
involvement of the hippocampus not only in the pathophys-
iology of MDD but also in treatment outcome (MacQueen
et al., 2008; McKinnon et al., 2009). Larger hippocampal vol-
ume was also associated with a lower probability of relapse
(Kronmüller et al., 2008). Microstructural abnormalities in the
hippocampus have been suggested to indicate the vulnerabil-
ity to treatment resistance (Ruhé et al., 2012). Further, a recent
study pointed to a crucial role of the right insula: indeed, insula
hypometabolism (detected via PET) was associated with poor
response to escitalopram while the opposite was observed con-
cerning cognitive behavior therapy, as insula hypometabolism
was associated with good response to this cognitive therapeutic
approach (McGrath et al., 2013). This indicates that neuroimag-
ing can also help in selecting the appropriate treatment, and
that brain activity does not predict poor response to treatment
in a general way, but poor response to a particular therapeutic
approach.
The crucial role of corticolimbic areas in the response to AD
therapy has also been highlighted by recent impressive preclinical
studies. These studies highlight the mechanisms underlying AD
action in a given region. For example, Vialou et al. (2010) demon-
strated that DeltaFosB induction in the nucleus accumbens was
required for the effects of fluoxetine in the social defeat test,
whereas Li et al. (2010) demonstrated that the effects of ketamine
require synapse formation (particularly mTor-dependent synapse
formation) in the PFC. Further, a recent paper showed that neural
activity in the visual cortex during emotional processing predicts
the response to scopolamine in depression (Furey et al., 2013).
Finally, TRD and/or treatment non-response can also be
indirectly approached by studying the mechanism of non-
pharmacological treatments, including vagus nerve stimulation
therapy (VNS), ECT, and DBS. VNS is approved for the treat-
ment of TRD. In VNS, a battery-powered generator is implanted
in the chest wall and connected to a wire wrapped around the
left vagus nerve in the neck. This wire sends intermittent elec-
trical pulses through the vagal afferent connections to the brain-
stem, which may alter information processing in brain regions
to which it projects, including the noradrenergic locus cœruleus
and serotonergic nuclei as well as the thalamus, hypothalamus,
central amygdala nucleus, bed nucleus of the stria terminalis,
and nucleus accumbens, which are all disrupted during MDD.
Functional imaging suggests that VNS leads to activity changes
in the hypothalamus, orbitofrontal cortex, amygdala, hippocam-
pus, insula, medial PFC, and cingulate (Bohning et al., 2001;
Zobel et al., 2005), suggesting that VNS might aid in the recovery
of MDD patients by reversing the pathophysiological alterations
observed in MDD. ECT is based on the administration of brief
electrical pulses to the scalp to induce depolarization of cortical
neurons and thus brain seizures. It is among the most effec-
tive treatments for TRD and AD non-response. The mechanism
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of action of ECT remains a mystery, but the recent observation
that electroconvulsive shock, the animal analogue of ECT, stimu-
lates precursor cell proliferation in the subgranular zone of the
dentate gyrus as well as hippocampal neurogenesis in the rat
(Madsen et al., 2000) and monkey (Perera et al., 2007) suggests
that pharmacological treatments and ECT may target a common
endpoint, such as neuronal plasticity. Finally, because a number
of clinical studies have demonstrated long-term effects of DBS in
terms of improving symptoms of MDD (Bewernick et al., 2012;
Lozano et al., 2012), the study of the neurobiological mechanisms
underlying the beneficial effects of DBS will contribute to the
understanding of TRD and of the mechanisms underlying poor
response to AD. For example, a recent study by Schmuckermair
et al. (2013) in a mouse model of TRD demonstrated that
repeated nucleus accumbens DBS reversed depression-related
behavior and coincided with changes in stress-induced neuronal
activation of prelimbic, infralimbic, and cingulate areas in the lat-
eral habenula and in the dentate gyrus of the hippocampus, where
neurogenesis was also increased. In addition, Hamani et al. (2010)
demonstrated that DBS in the rat ventromedial PFC induced a
clear AD-like effect that was dependent on the integrity of the
serotoninergic system.
NEUROTRANSMISSION AND RESPONSE TO ANTIDEPRESSANTS
Serotoninergic system
Because TCAs and SSRIs increase serotonin (5-HT: 5-
hydroxytriptamine) availability in the synaptic cleft, the
level of involvement of 5-HT in predicting AD response has
been a focus of research. Consistent with predictions, tryptophan
depletion (which is a precursor of the 5-HT synthesis) in subjects
successfully treated with SSRI prevents AD effects (Delgado
et al., 1999), indicating that 5-HT is essential for the action of
SSRIs. More recently, the utilization of PET permitted the precise
localization of this 5-HT action. SSRI treatment outcome was
related to serotonin transporter (SERT) ratios between the raphe
nuclei and serotonergic projection areas (habenula, amygdala,
hippocampus, and subgenual cingulate cortex) before treatment
(Lanzenberger et al., 2012). In animal models, depletion of
5-HT tissue content by para-chlorophenylalanine, an inhibitor
of tryptophan hydroxylase (TPH), prevented the acute effects of
SSRIs in a bioassay (O’Leary et al., 2007). Rodent studies also
permitted the determination of the precise molecular target of
AD action, particularly through the use of knockout mice for
SERT and several 5-HT receptors. As expected, in a bioassay
assessing effects of sub-acute injections of AD, the action of
fluoxetine was abolished in SERT knockout mice, whereas
the effect of a noradrenaline-preferring AD, desipramine, was
conserved (Holmes et al., 2002). Once the blockade of the SERT
has been achieved, the increased 5-HT in the synaptic cleft will
bind to several 5-HT receptors. One of the most studied is the
5-HT1A postsynaptic receptor. In initial studies, SSRIs failed to
alter immobility in 5-HT1A mutant mice, suggesting that 5HT1A
receptors are critical for the expression of AD-like responses to
SSRIs (Mayorga et al., 2001; Santarelli et al., 2003). However,
a more complex picture later emerged as other studies showed
that the effects of SSRIs were still present in 5-HT1A mutant
mice (Guilloux et al., 2006; Holick et al., 2008). In fact, the use
of 5-HT1A mutants did not allow to distinguish the pre- and
the post-synaptic 5-HT1A receptors, and it is probable that the
involvement of these receptors during chronic SSRIs is dynamic,
as in the initial phase of the treatment the action of 5-HT on
the 5-HT1A somatodendritic receptors may oppose the action
on the post-synaptic receptors, while during the second phase,
the presynaptic receptors get desensitized (see below). It has
also been shown that desipramine, a NRI, still exerts an AD-like
effect in 5HT1A receptor knockout mice despite reduced baseline
immobility in the tail suspension test (Mayorga et al., 2001).
However, the action on the postsynaptic 5-HT1A receptors is
compromised by a concomitant action on 5-HT1A autoreceptors
located in the raphe, which reduces the clinical efficacy of SSRIs
and partly explains their delayed onset of action. Using condi-
tional knockout mice for pre-synaptic 5-HT1A receptors, it was
observed that reduction of 5-HT1A-autoreceptor expression with
unchanged post-synaptic 5-HT1A receptor expression induced
AD-like behavior and augmented SSRI effects (Richardson-
Jones et al., 2010). These observations were recently confirmed
using another experimental strategy, intra-raphe infusion of
small-interfering RNA (siRNA) sequences directed toward the
5-HT1A autoreceptors. The siRNA decreased the expression of
these receptors without affecting post-synaptic 5-HT1A receptors,
concomitant with a robust and rapid AD-like effect (Bortolozzi,
Castañé, Semakova, Santana, Alvarado and Cortés, 2012).
The involvement of 5-HT1B receptors is complex and depends
upon the class of AD used, as well as on the methodology used
to study their contribution (knockouts or pharmacological stud-
ies). Indeed, in 5HT1B receptor knockout mice, desipramine still
has AD-like effects (Mayorga et al., 2001) while pharmacological
blockade of the 5-HT1B receptors with GR 127935 or SB216641
(5-HT1B receptor antagonists) potentiated the effects of the drug
(Tatarczyñska et al., 2004). Concerning SSRIs, an increased sen-
sitivity to these compounds has been observed in mutants (single
mutants for the 5-HT1B receptors) or after 5-HT1B receptors
antagonists (Mayorga et al., 2001), whereas other studies reported
SSRI resistance in themutants (Trillat et al., 1998). Finally, in dou-
ble knockout for 5-HT1A and the 5-HT1B receptors the response
to acute SSRI was impacted, but not the one to chronic SSRIs
(Guilloux et al., 2011). Other 5-HT receptors are required for AD
action, including the 5-HT2B (Diaz et al., 2012), 5-HT2C (Cryan
and Lucki, 2000a) and 5-HT4 receptors (Cryan and Lucki, 2000b;
Lucas et al., 2007).
Genetic studies confirmed the involvement of 5-HT-related
targets in the outcome of 5-HT therapy. For example, different
studies indicated a polymorphism in the human gene encod-
ing SERT (SLC6A4) as a predictor of response to AD. Heils
et al. (1996) identified a functional polymorphism in the tran-
scriptional region upstream of the SLC6A4-coding sequence
(5-HTTLPR) that affects SLC6A4 expression, in which the l
allele yields twofold higher SLC6A4 expression in the basal state
than the s form. In a meta-analysis of the literature, Kato and
Serretti (2010) demonstrated that the l variant is associated
with a better response rate to AD than the s allele. Nakamura
et al. (2000) further examined the polymorphic region and con-
cluded that the alleles previously reported as s and l should be
respectively divided into four (14A, 14B, 14C, and 14D) and
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six allelic variants (16A–16F). Smeraldi et al. (2006) demon-
strated that among carriers of the l variant, 16F l carriers
exhibited only a partial response to AD and 16D l carriers
exhibited a marginally better response than 16A l allele carri-
ers. Another polymorphism of SLC6A4 has been associated with
an increased response to ADs; carriers with the 12 allele dis-
played a greater response to ADs, particularly when this allele
was also associated with the l variant of the SERT-linked poly-
morphic region (5-HTTLPR) gene (see (Kato and Serretti, 2010)
for a review). However, these findings have not been consistently
replicated.
Serotonin biosynthesis involves TPH. This enzyme has two iso-
forms encoded by TPH1 and TPH2 genes, and SNPs of both genes
have been reported. A significant association of TPH1 218A/C
with response to ADs has been reported (Serretti et al., 2001) but
these findings were not replicated (Kato et al., 2007).
A total of 50 SNPs of the 5-HT1A receptor gene have been
described. Of particular interest is the 1019C/G (rs6295) SNP,
which is related to the altered expression and function of 5-HT1A
receptors. Indeed, the G allele is associated with an increase in
5-HT1A autoreceptors and thus a decrease in 5-HT neurotrans-
mission. An association of this polymorphism with AD response
was found only in Asian and not in Caucasian populations (Kato
and Serretti, 2010). Two important common SNPs of the gene
encoding the 5-HT2A receptor, 102T/C and 1438A/G, have been
described: the C variant of the 102T/C SNP is associated with
lower 5-HT2A receptor expression compared to the T variant,
whereas the A variant of the 1438A/G SNP increases promoter
activity compared to the G variant. Interestingly, the AD response
was higher among the G/G genotype carriers than among the A/G
or A/A carriers, although only in the Asian population (Kato and
Serretti, 2010).
Polymorphisms combine with environmental factors in the
etiology of MDD (El-Hage et al., 2009). For example, stressful
life events predict a better response to escitalopram, but poly-
morphisms in 5-HT related genes, such as 5-HTTLPR, alter these
effects (Keers et al., 2011). Assessment of 5-HT-related polymor-
phisms or pre-treatment PET of 5-HT molecular targets would
improve the prediction of treatment response. Specifically, tar-
geting 5-HT1A autoreceptors to eliminate their initial negative
contribution during AD therapy would accelerate the onset of the
beneficial effects of AD therapy.
Noradrenergic system
Drugs such as the TCA desipramine, and other TCAs that
increase noradrenaline and serotonine neurotransmission, as well
as the NRI reboxetine act by binding to the noradrenaline trans-
porter which increases noradrenaline levels in the synaptic cleft,
activating noradrenergic receptors. The enzyme dopamine beta-
hydroxylase (Dbh) is responsible for the synthesis of epinephrine
and noradrenaline. Mice unable to synthesize noradrenaline and
epinephrine due to targeted disruption of the Dbh gene did not
exhibit altered behavior in bioassays for depressive-like behav-
ior, but ADs with a noradrenergic-preferring action such as
desipramine or reboxetine failed to exert AD-like effects (Cryan
et al., 2001). The same results were obtained with the MAOI
pargyline and the atypical AD bupropion (Cryan et al., 2004).
Surprisingly, the effects of the SSRIs fluoxetine, sertraline, and
paroxetine were also absent or severely attenuated in Dbh knock-
out mice while the effects of another SSRI, citalopram, were not
altered. Restoration of a normal noradrenergic level by L-threo-
3,4-dihydroxyphenylserine restored the behavioral effects of both
desipramine and paroxetine in the knockout mice, demonstrat-
ing that the AD non-response was due to altered noradrener-
gic function rather than developmental abnormalities resulting
from chronic noradrenaline deficiency. Thus, noradrenaline may
be involved in the effects of not only noradrenaline-acting AD
drugs but also 5-HT-acting compounds. The beneficial action
of noradrenergic-acting compounds in the treatment of MDD
may be related to the α2-adrenergic receptor because the AD-
like effects of desipramine are reversed by α2-adrenergic recep-
tor antagonists, such as yohimbine or idazoxan (Yalcin et al.,
2005; Zhang et al., 2009). Other adrenergic receptors are also
involved: the cognitive effects of these treatments are mediated by
post-synaptic α1-adrenergic receptors in the mPFC (Bondi et al.,
2010). However, β2 or β3 adrenergic receptors do not appear to
play a pivotal role in AD effects (Zhang et al., 2009; Stemmelin
et al., 2010).
Finally, the involvement of organic cation transporter 2
(OCT2) in non-response to AD is also of note. OCT2 is involved
inmonoamine clearance, andmice deficient in this protein exhib-
ited an altered response to AD (Bacq et al., 2012).
The contribution of the noradrenergic system to AD effects
is largely confirmed by genetic data. Several polymorphisms of
the gene encoding the noradrenalin transporter (SLC6A4) have
been associated with AD response, particularly the rs2242466
(–182T/C) and rs5569 (1287G/A) polymorphisms (Shiroma
et al., 2010). Catechol-O-methyltransferase (COMT) plays a piv-
otal role in the degradation of noradrenalin and dopamine.
Interestingly, the Val158Met (rs4680) polymorphism of the
COMT gene is associated with AD response (Benedetti et al.,
2009; Tsai et al., 2009). Baune et al. (2008) demonstrated a
negative influence of the higher activity COMT 158Val/Val geno-
type on AD response during the first 6 weeks of treatment,
possibly due to the consequent decrease in dopamine availabil-
ity. MAOA is involved in the degradation of monoamines, and
polymorphisms of MAOA have been associated with fluoxetine,
paroxetine, or mirtazapine response (Yu et al., 2005; Tadic´ et al.,
2007; Domschke et al., 2008b).
Xu et al. (2011) found that early life stress may interact with
the SLC6A2 polymorphism to alter AD response. Such effects
might occur via epigenetic mechanisms, such as methylation or
acetylation.
The assessment of polymorphisms of noradrenergic-related
genes would improve the prediction of AD response. Combining
ADs with α2-adrenergic receptor agonists could also improve the
response rate or accelerate the onset of therapeutic action.
Other neurotransmission systems
One reason for non-response to ADs targeting monoaminer-
gic neurotransmission is that these drugs may be ineffective in
patients with alterations of other neurotransmission systems. For
example, psychomotor retardation, a symptom exhibited by a
subgroup of patients with MDD, has been related to a deficit in
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dopaminergic neurotransmission, particularly in the dorsolateral
PFC. Consequently, these patients may preferentially benefit from
treatment directly targeting dopaminergic neurotransmission.
This has been explored by Taylor et al. (2006), who demonstrated
that MDD patients with reduced pre-treatment performance on
neuropsychological tests had a poor outcome after 12 weeks of
fluoxetine treatment.
Substance P has also been suggested to have a key role in AD
response. For example, decreased substance P in the cerebrospinal
fluid has been associated with poor response to ADs (Carpenter
et al., 2008). This conclusion is supported by convincing genetic
data because the D allele of the angiotensin-converting enzyme
(ACE) gene, which is related to higher ACE plasma levels, is asso-
ciated with higher substance P levels and a more rapid onset of
AD response (Baghai et al., 2004; Bondy et al., 2005; Narasimhan
and Lohoff, 2012).
There is increasing evidence for the involvement of glutamate
neurotransmission in MDD, and glutamate receptors are now
being explored as targets for the treatment of MDD. For example,
a clinical effect was observed when riluzole, a glutamatergic-
acting compound, was added to ongoing AD therapy in TRD
patients (Sanacora et al., 2007, 2008). Ketamine has a rapid AD
effect and improves symptoms in TRD patients or in patients not
responding to ECT (Ibrahim et al., 2011).
This is confirmed by genetic studies. For example, studies
have found an association between a SNP of the dystrobrevin-
binding-protein 1 gene, which is involved in glutamatergic neu-
rotransmission, and AD response (Pae et al., 2007b; Kim et al.,
2008). Furthermore, according to the STAR*D study, a SNP
(rs1954787) of the GRIK4 (glutamate receptor ionotropic kainate
4) gene encoding kainate receptor subunit 1 is associated with
response to citalopram (Mayer, 2007; Horstmann and Binder,
2009; Stawski et al., 2010; Narasimhan and Lohoff, 2012). This
was confirmed in another cohort, the “Munich Antidepressant
Response Signature” (MARS) project (Horstmann et al., 2008,
2010; Porcelli et al., 2011). Horstmann et al. (2010) identi-
fied another SNP (rs12800734) in the GRIK4 gene that is more
strongly associated with response to treatment.
Data to support the involvement of GABA (gamma-
aminobutyric acid) in the response to ADs are sparse, and this
neurotransmitter does not appear to have a pivotal role in AD
effects. However, mice with a deletion of the gene encoding the
GABA transporter subtype 1 (GAT1), which transports extracel-
lular GABA into presynaptic neurons, exhibited non-response to
fluoxetine and amitriptyline (Liu et al., 2007a).
The endocannabinoid system is a modulatory system with
both central and peripheral actions. Two cannabinoid receptors
have been characterized: CNR1 located predominantly in the
brain, and CNR2 in peripheral immune tissue and in glial cells
in the central nervous system. Interestingly, knockout mice for
the CNR1 receptor displayed attenuated response to desipramine
and paroxetine (Steiner et al., 2008). Mitjans et al. (2012, 2013)
demonstrated that genetic variability in endocannabinoid recep-
tors could play a role in clinical response. Specifically, molecular
variations in the CNR1 gene appear to differentiate the response
to citalopram according to sex. In an analysis of SNP vari-
ability in the CNR1 gene, Domschke et al. (2008a) reported
that the G allele of rs1049353 leads to increased risk of non-
response to in female patients. These results suggest a role of
the CNR1 gene in the etiology of MDD and clinical response to
citalopram.
Leptin signaling may be involved in the pathophysiology of
MDD. Kloiber et al. (2013) recently suggested an association
of polymorphisms in the leptin gene with failure of AD to
achieve remission. In this study, decreased leptin serum levels and
reduced leptin mRNA expression were detected in patients with
impaired treatment response, independently of their genotype
configuration.
Endogenous opioids are involved in the regulation of mood
and behavior. Three receptors (mu, delta, and kappa) inter-
act with a family of endogenous opioid peptides (β-endorphin,
enkephalins, and dynorphins). Studies in amousemodel ofMDD
have demonstrated that the combination of monoaminergic ADs
and opioid receptor agonists can produce synergistic AD effects
(Berrocoso andMico, 2009). Themu receptor has been associated
with citalopram response (Garriock et al., 2010). Haj-Mirzaian
et al. (2013) demonstrated that elevated levels of endogenous opi-
oids and nitric oxide due to bile-duct ligation in mice induced an
AD-like effect. The effect was reversed by blockade of the nitrergic
and opioid systems, suggesting an involvement of these systems in
non-response. However, it is difficult to evaluate the risk-benefit
balance of currently available mu opioid receptors agonists as
ADs, partly because of their inherent abuse liability.
NEURAL PLASTICITY AND RESPONSE TO ANTIDEPRESSANTS
Molecular aspects
Once the AD has increased monoamines in the synaptic cleft or
bound to post-synaptic serotoninergic or noradrenergic recep-
tors, it activates second messengers, such as the cyclic adenosine
monophosphate (cAMP) pathway, leading to the production
of cAMP-dependent protein kinase (PKA). This activation may
in turn stimulate nuclear transcription factors, such as cAMP
response element binding protein (CREB), via phosphoryla-
tion. Activated CREB enhances the transcription of many tar-
get genes, including brain-derived neurotrophic factor (BDNF),
which exerts its effects mainly by binding to its specific recep-
tor: the tyrosine receptor kinase B (TrkB). Consequently, non-
response to AD has been investigated in relationship to alterations
of these targets, particularly when polymorphisms of the genes
encoding these proteins have been reported.
BDNF secretion and intercellular trafficking are related to a
SNP in the BDNF gene that causes a valine to methionine sub-
stitution (Val66Met). A meta-analysis by Kato and Serretti (2010)
indicated a better response to ADs in Met allele carriers. Other
neurotrophic/growth factors have also been implicated in TRD
and/or in AD response, including vascular endothelial growth fac-
tor (VEGF), fibroblast growth factor 2, and insulin-like growth
factor 1 (IGF-1).
In CREBmutantmice (CREBaD), the SSRI fluoxetine andNRI
desipramine still induce AD-like effect in bioassays for depres-
sive behavior (Conti et al., 2002). This effect is accompanied by
a desipramine-induced attenuation of the stress-induced activa-
tion of the HPA axis in both CREBaD-deficient and control mice
(Conti et al., 2002). Interestingly, the AD-induced increase in
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BDNF in the cortex and hippocampus is absent in CREBaD-
deficient mice (Conti et al., 2002), indicating that CREB may be a
critical mediator of the transcriptional effects of AD.
Heterozygous bdnf +/− mice, in which the levels of BDNF
in the brain are reduced by approximately half, and mice with
an inducible deletion of bdnf in the forebrain exhibited blunted
AD response in the forced swim test (Saarelainen et al., 2003;
Monteggia et al., 2004). This result is related to the alteration
of BDNF in the dentate gyrus of the hippocampus. Indeed, the
selective deletion of BDNF in the dentate gyrus but not the CA1
region is sufficient to attenuate the effects of desipramine and
citalopram in the forced swim test (Adachi et al., 2008). Further,
in the BDNFMet/Met mice, chronic fluoxetine is no more able to
reverse stress-related behavior (Chen et al., 2006; Yu et al., 2012),
to increase hippocampal BDNF levels and to stimulate dentate
gyrus synaptic plasticity (Bath et al., 2012). It is, however, to note
that the action of desipramine is still present (Yu et al., 2012),
which suggests a specific contribution of the 5-HT system in these
effects. These findings are coherent with clinical findings as it was
observed that serum levels of BDNF were low in MDD patients
and this normalizes after remission (Molendijk et al., 2011). The
molecular target of BDNF is TrkB, and mice with a conditional
deletion of the TrkB gene restricted to the forebrain do not
respond to ADs (Saarelainen et al., 2003). Similar results were
observed in Aquaporin-4 (AQP4) knockout animals. AQP4 is a
key molecule for maintaining water homeostasis in the CNS that
is expressed in adult neural stem cells and astrocytes. AQP4 inval-
idation disrupts the chronic fluoxetine-induced enhancement of
adult mouse hippocampal neurogenesis (which is also a process
crucially involved in the AD response; see next section) as well as
AD-evoked behavioral improvement under both basal conditions
and a chronic, mild stress-evoked depressive state (Kong et al.,
2009).
Stress induces changes in the brain that can persist for the
lifespan. Variations in genes implicated in 5-HT neurotransmis-
sion may interact with environmental factors to influence AD
response (El-Hage et al., 2009). One group of signaling path-
ways involved in the cellular stress response includes the family
of mitogen-activated protein kinases (MAPKs). Bruchas et al.
(2011), focusing on the dorsal raphe nucleus, a brain region in
which corticotropin-releasing factor, kappa-opioid receptors, and
5-HT systems converge, demonstrated that social defeat stress
causes an increase in the activity of the intracellular signaling
molecule p38αMAPK. They demonstrated that p38αMAPK acti-
vation within the dorsal raphe nucleus is responsible for the abil-
ity of stress to trigger depressive-like states. They demonstrated
that in 5-HT neurons, p38αMAPK acts to directly influence SERT
trafficking and ultimately increase the rate of 5-HT reuptake.
Another key molecular player in the response to monoamin-
ergic ADs is p11. Indeed, p11 is downregulated in several
brain regions of MDD patients or in animal models of MDD
(Svenningsson et al., 2006; Alexander et al., 2010), whereas ADs
and ECT increase p11 in the frontal cortex and hippocam-
pus (Svenningsson et al., 2006; Warner-Schmidt et al., 2010;
Oh et al., 2013). This response appears to be related to BDNF
because p11 is reduced in mice in which BDNF is downregu-
lated and increased in mice in which BDNF is overexpressed
(Warner-Schmidt et al., 2010). p11 is also regulated by gluco-
corticoids (Zhang et al., 2008) and pro-inflammatory cytokines
(Warner-Schmidt et al., 2011). Mice that lack p11 throughout
their body display a depressive-like phenotype (Svenningsson
et al., 2006; Warner-Schmidt et al., 2009, 2010), and more inter-
estingly, the response to AD drugs is reduced in these mice
(Svenningsson et al., 2006; Egeland et al., 2011; Eriksson et al.,
2013). Interestingly, the accumbens-restricted overexpression of
p11 is sufficient to induce the depressive-like phenotype in mice
but does not modify the response to ADs (Alexander et al., 2010),
whereas ablation of p11 from pyramidal projection neurons in the
cortical layer 5A does not alter depressive-like behavior but results
in a diminished response to ADs (Schmidt et al., 2012a), indi-
cating that the mechanisms underlying the pathophysiology of
MDDmight differ from the mechanisms underlying the response
to ADs.
Recent studies have provided evidence for a BDNF gene ×
environment interaction. Stress and ADs have opposing actions
on BDNF and neurogenesis. Stress decreases and ADs increase
the expression of BDNF in the dentate gyrus granule cell layer.
These changes contribute to the regulation of neurogenesis by
stress and ADs (Duman and Li, 2012). Mutant mice with a het-
erozygous deletion of BDNF, which results in the expression of
approximately half the normal levels of BDNF, display normal
behavior under baseline conditions but exhibit a depressive phe-
notype upon exposure to stress and an altered response to ADs
(Duman et al., 2007; Ibarguen-Vargas et al., 2009).
Other factors have been implicated in the response to AD
(e.g., zinc and cytokines). Clinical evidence suggests that zinc
deficiency induces depression- and anxiety-like behaviors. Zinc
administration improves the efficacy of ADs in MDD patients
and may be particularly relevant for TRD patients. Recent inves-
tigations on the molecular mechanisms responsible for these
observations suggest a role for zinc in the regulation of neuro-
transmitters, antioxidant mechanisms, neurotrophic factors and
neuronal precursor cells. The presynaptic release of zinc from
axon terminals of glutamatergic neurons is prominent in the
hippocampus, where zinc exerts complex pleiotropic effects on
neuronal plasticity, neurogenesis, and neuronal viability, affecting
learning, memory, and emotional regulation (Swardfager et al.,
2013). The neuroprotective properties of zinc at physiological
concentrations may be attributable to the blockade of excito-
toxic Ca2+ in?ux and upregulation of cellular antioxidant sys-
tems. Chronic zinc administration can increase BDNF expression
(Swardfager et al., 2013).
Conboy et al. (2011) explored the expression of macrophage
migration inhibitory factor (MIF) in astrocytes and neurogenic
cells in the subgranular zone of the rodent dentate gyrus and
characterized its presence in stem cells, cells undergoing prolif-
eration, and recently proliferated cells undergoing maturation.
They found that MIF deficiency is associated with a phenotype
characterized by increased anxiety- and depression-like behav-
iors. Furthermore, they determined that in the subgranular zone
of the hippocampus, macrophage MIF expression is modulated
in parallel with cell proliferation by stress, glucocorticoid levels,
and fluoxetine. Both the genetic deletion of MIF and chronic
treatment with the MIF antagonist Iso-1 resulted in reduced
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cell proliferation, and MIF deletion also abolished the enhanced
proliferation induced by chronic fluoxetine.
Moon et al. (2012) provided evidence that macrophage MIF is
regulated by long-term exercise and that it mediates induction of
serotonin and neurotrophic factors, resulting in the amelioration
of depressive behaviors in a rodent model. MIF was upregulated
during both long-term voluntary exercise and repeated electro-
convulsive seizure treatments. The authors demonstrated that
MIF induced TPH2 and Bdnf expression in the rat brain along
with ERK1/2 activation, resulting in an increase in 5-HT levels
by MIF. In addition, direct intra-brain administration of MIF
induced an AD-like response in the forced swim test. These results
demonstrate that MIF induces AD-like behavior and mediates
the effect of exercise on mood improvement (Moon et al., 2012).
Physical activity has neuroimmune effects that are likely involved
in enhanced neuroplasticity, reduced oxidative stress, increases in
5-HT, dopamine, and noradrenaline, and enhanced glucocorti-
coid sensitivity (Eyre et al., 2013). Thus, physical activity should
be recommended in addition to AD therapy to improve drug
response.
Cellular targets
In the past 15 years, the process leading to the generation of
new neurons in the adult hippocampus (adult neurogenesis) has
been shown to be compromised in rodent models of MDD;
this effect is prevented by administration of monoaminergic AD
drugs (see Hanson et al., 2011; Eisch and Petrik, 2012; Petrik
et al., 2012; Bambico and Belzung, 2013; Tanti and Belzung,
2013a,b for recent reviews). These data have been corroborated
by clinical studies (Boldrini et al., 2009, 2012, 2013), although
some contradictory findings have been initially reported (Reif
et al., 2006). Furthermore, these data extend beyond pharma-
cotherapy, as increase in hippocampal neurogenesis has also been
observed after ECT (Malberg et al., 2000) or VNS (Revesz et al.,
2008). However, increase in adult hippocampal neurogenesis
alone is insufficient to induce AD-like effects (Sahay et al., 2011).
Interestingly, studies have established that the ability of AD treat-
ments to stimulate neurogenesis applies to all phases of the gen-
eration of new cells (proliferation, maturation) and is observed in
the ventral and dorsal hippocampus (Tanti and Belzung, 2013b).
Furthermore, adult hippocampal neurogenesis is not only a cor-
relate of the therapeutic action of monoaminergic drugs but
appears to be essential to achieve recovery. Indeed, abolition of
hippocampal neurogenesis by focal X-ray hippocampal irradia-
tion suppresses some and/or all behavioral effects of fluoxetine
and/or imipramine in animals (Santarelli et al., 2003; Airan et al.,
2007; Surget et al., 2008, 2011; Wang et al., 2008b; David et al.,
2009; Perera et al., 2011). Similar results are observed after genetic
ablation of adult neurogenesis (Lehmann et al., 2013). However,
the situation is more complicated if we consider the effects of
newly developed putative ADs: indeed, whereas the effects of a
CNR1 ligand are abolished by suppression of neurogenesis (Jiang
et al., 2005) as observed with monoaminergic-acting compounds,
most of the AD-like effects of MCHR1 (Melanin-concentrating
hormone receptor 1), CRH1 (corticotrophin-releasing hormone),
or V1b (Vasopressin V1b) antagonists are not prevented by abla-
tion of neurogenesis (David et al., 2007; Surget et al., 2008). This
result indicates that although the ability of the treatments used
in the clinic (which all target monoaminergic systems) to elicit
remission relies on neurogenesis, the therapeutic effects of a drug
can also be achieved via neurogenesis-independent mechanisms.
For example, the dual orexine receptor almorexant induces AD-
like effects but can decrease neurogenesis in some cases (Nollet
et al., 2012), and rTMS suppresses the survival rate of proliferat-
ing cells (Czéh et al., 2002). The ability of new cells to contribute
to recovery requires the incorporation of the new neurons into a
functional network, which occurs when these cells are 4–8 weeks
old. Thus, the use of an anti-mitotic agent to suppress neurogen-
esis revealed that the ablation of 2-week-old cells did not modify
the effects of ADs (Bessa et al., 2009), whereas the 4-week-old cells
are recruited after successful AD therapy to facilitate the regu-
lation of the HPA axis after disruption by chronic stress (Surget
et al., 2011). Therefore, it appears that hippocampal neurogenesis
can be considered a process underlying AD non-response, related
to the generation of new functional neurons.
The essential role of adult hippocampal neurogenesis in
achieving remission is further supported by the observation that
environmental factors that contribute to remission also act on
adult hippocampal neurogenesis. Indeed, environmental enrich-
ment and running both enable recovery and stimulate neu-
rogenesis. Furthermore, the AD-like effects of environmental
enrichment are suppressed by genetic abolition of neurogenesis
(Schloesser et al., 2010). Factors associated with higher AD non-
response, such as aging, are also related to lower hippocampal
neurogenesis (Couillard-Despres et al., 2009).
Several hypotheses have been formulated regarding the func-
tion of adult hippocampal neurogenesis. According to some
authors, this process might be crucial for pattern separation
(Clelland er al., 2009; Sahay et al., 2011; Nakashiba et al., 2012;
Tronel et al., 2012), a process that enables the differentiation of
two closely overlapping stimuli. Thus, a deficit in pattern sep-
aration might lead to overgeneralization and cognitive bias. A
restoration of such a deficit could contribute to remission. Others
claim that hippocampal neurogenesis is required for contextual
memory (Shors et al., 2001; Dupret et al., 2008; Deng et al., 2009;
Trouche et al., 2009). Hippocampal neurogenesis is essential for
regulation of the HPA axis (Schloesser et al., 2009; Snyder et al.,
2011; Surget et al., 2011), and an increase in neurogenesis might
facilitate recovery via normalization of HPA axis function. Finally,
hippocampal neurogenesis have also been proposed to be cru-
cial for anxiety behavior (Revest et al., 2009; Fuss et al., 2010;
Mateus-Pinheiro et al., 2013) or executive functions (Burghardt
et al., 2012); if restored, these functions would enable the sub-
ject to react more accurately to the environment. Interestingly,
all of the above-mentioned processes are disturbed in MDD and
could be essential to achieving remission (see Tanti and Belzung,
2013a,b, for reviews).
If hippocampal neurogenesis is crucial in achieving remission,
any strategy that leads to an increase in the number of new neu-
rons in this structure could facilitate recovery or accelerate the
onset of therapeutic outcome when combined with ADs. Several
processes have been shown to increase neurogenesis, including
environment enrichment, physical exercise, and learning. Thus,
one can speculate that combining any of these activities with AD
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treatment could increase the therapeutic outcome of pharma-
cotherapy.
HORMONAL TARGETS AND RESPONSE TO ANTIDEPRESSANTS
HPA axis regulation
It has been repeatedly demonstrated that ∼50% of patients with
MDD exhibit a dysfunction of the tuning of the HPA axis (Young
et al., 1991; Holsboer, 2000; Pariante and Miller, 2001; Pariante,
2003), which can be measured using the dexamethasone-
suppression test or combined dexamethasone/CRH test. Indeed,
these patients exhibit dexamethasone non-suppression, indicat-
ing a defect in the negative feedback that enables the suppression
of the secretion of glucocorticoids in healthy subjects. This dys-
regulation is restored after effective AD therapy, and interestingly,
the therapeutic action of the treatment only occurs once nor-
mal feedback of the HPA axis has been restored (see Belzung
and Billette De Villemeur, 2010, for a review), indicating that
restoration of the HPA axis regulation is mandatory to enable
recovery. Interestingly, normalization of HPA axis overactivity
also occurs after successful ECT (Kling et al., 1994), indicat-
ing that this property goes beyond classical pharmacotherapy.
Thus, the tuning of the HPA axis may be related to the ability
to achieve a therapeutic outcome after treatment. If this outcome
cannot be achieved, a resistance and/or non-response to treat-
ment should be observed (Ising et al., 2007; Binder et al., 2009;
Hennings et al., 2009; Schüle et al., 2009; Horstmann et al.,
2010). This relationship has been demonstrated: a defect in HPA
axis regulation is not only a signature of MDD or of remis-
sion but also a predictor of treatment non-response. Indeed,
using the combined dexamethasone/CRH test, Brouwer et al.
(2006) demonstrated that the AD response rate in high-ACTH
patients was significantly lower than that in intermediate-ACTH
patients. Similar results have been reported by Ising et al. (2007),
who demonstrated that patients who do not exhibit a reduc-
tion of the cortisol response to a dexamethasone/CRH test after
2–3 weeks of treatment are not likely to respond to the current
treatment. However, this has not been confirmed in two other
studies (Paslakis et al., 2010; Carpenter et al., 2011). For example,
Carpenter et al. (2011) rather found an increased pre-treatment
cortisol after DEX/CRH to be associated with sertraline response.
Possibly, rapid initial improvement of the cortisol response fol-
lowing DEX/CRHwould be amore effective predictor of response
outcome.
At the molecular level, the negative feedback on the HPA
axis mainly occurs via the binding of glucocorticoids, such as
cortisol or corticosterone, on specific receptors, such as the glu-
cocorticoid receptors (GRs), which have low affinity for gluco-
corticoids and are thus only activated when a high level of stress
hormones is present. The mode of action of GRs is very com-
plex: in the absence of glucocorticoids, GRs are packaged into
a large molecular complex consisting of chaperone heat-shock
proteins, such as hsp90 and hsp70, and co-chaperones, such as
FKBP51, which bind to the receptor and keep it inactive, thus
decreasing the affinity of GRs for glucocorticoids. High FKBP51
induces inhibition of glucocorticoid-related GR activation, and
thus, FKBP51 can be considered a negative feedback loop regulat-
ing GRs (Schmidt et al., 2012b). Interestingly, in MDD subjects,
peripheral FKBP51 reduction is a marker for successful AD ther-
apeutic outcome because FKBP51 levels are diminished in AD
responders but not non-responders(Cattaneo et al., 2013).
The contribution of HPA regulation to treatment outcome
after AD has been confirmed by studies investigating the con-
tribution of genes involved in the tuning of the stress axis after
treatment. Most findings concern the FKBP5 gene. Several reports
have investigated the association of FKBP5 polymorphisms with
the response to AD drugs. In 2004, a strong association between
polymorphisms of the FKBP5 gene and the response to AD was
observed in 280 depressed patients of the MARS sample (Binder
et al., 2004). These results were subsequently replicated in the
STAR∗D sample (Lekman et al., 2008) as well as in another
German sample (Kirchheiner et al., 2008). Interestingly, this rela-
tionship appears to be independent of the class of AD drug
because it was observed in patients treated with TCAs, SSRIs,
or mirtazapine. However, two smaller studies of Spanish and
Korean subjects reported negative associations in small samples
(Papiol et al., 2007; Tsai et al., 2007). In fact, in the patients
carrying the genotypes associated with faster response to AD, pre-
treatment HPA-axis dysregulation was low compared to other
patients (Binder et al., 2004), which might have facilitated the
normalization of the HPA-axis and thus recovery.
Polymorphisms of the GR gene have also been studied in asso-
ciation with treatment outcome. Studies have demonstrated that
the BclI and ER22/23EK polymorphisms are associated with the
response to ADs (Brouwer et al., 2006; van Rossum et al., 2006).
Other association studies have focused on the influence of poly-
morphisms in the CRHR1, CRHR2, and CRH-BP genes. Allele
G carriers at the rs2270007 site of the CRHR2 gene exhibited
a worse response to the SSRI citalopram (Papiol et al., 2007)
when compared to other alleles. Similarly, in a Chinese pop-
ulation, polymorphism at the rs242941 site of the CRH1 gene
has been associated with fluoxetine response (Liu et al., 2007b).
Finally, polymorphisms of genes related to hsp70 protein have
also been associated with poor response to AD (Pae et al., 2007a).
Taken together, these genetic studies strengthen the view that a
pre-treatment defect in HPA axis regulation may predict poor
treatment outcome.
Environmental studies further corroborate this assertion.
Hyperactivity of the HPA axis is related to chronic stress.
Interestingly, two recent publications reported that elevated stress
prior to treatment was associated with a good response to SSRIs
(Keers et al., 2010; Horacek et al., 2011). However, other studies
have shown the opposite (Monroe et al., 1992) or no association
(Bock et al., 2009). These discrepancies could be related to gene×
environment interactions because the effects of stress on treat-
ment outcome may vary according to genotype. For example, in
patients carrying more than one s allele of the SERT gene (which
is associated with increased vulnerability to stress), the occurrence
of a stressor predicted a poor response to ADs (Mandelli et al.,
2009; Keers et al., 2011). Similar findings were obtained using
a large sample of patients treated with escitalopram; in patients
carrying polymorphisms inducing vulnerability to stress, such as
polymorphism at the rs1360780 site of the FKBP5 gene and at
the rs110402 site of the CRHR1 gene, stressors were predictive of
response to treatment (Keers and Uher, 2012).
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FIGURE 1 | Mechanisms (in blue) associated with antidepressant therapy resistance and recommendations for clinical practice (in green).
Finally, evidence for the involvement of HPA axis feedback
dysregulation in AD non-response is also provided by data from
patients with diseases that are highly comorbid with MDD, such
as Cushing’s disease. Cushing’s disease is a syndrome related
to chronic glucocorticoid excess, due either to an overproduc-
tion of ACTH caused by a pituitary adenoma (66% of patients),
to an adrenal adenoma or carcinoma (24% of patients), or
to ectopic causes (10% of patients). Approximately half of the
patients display MDD (Sonino and Fava, 2002; Pereira et al.,
2010). Interestingly, MDD patients with Cushing’s disease are
poor responder to treatment with classical AD therapy (Sonino
et al., 1986, 1993), whereas a good therapeutic outcome can
be achieved by treatments that normalize the HPA overactivity
(Sonino and Fava, 2002; Pereira et al., 2010). These results con-
firm that excessive function of the HPA axis is associated with AD
non-response.
To improve drug response, pre-treatment HPA dysfunc-
tion should be assessed with the dexamethasone suppression
test or, preferably, the combined dexamethasone/CRH, as this
latter test appears to be more specific (Ising et al., 2007).
Polymorphisms of HPA-related genes, such as the FKBP5,
CRHR1, or GR genes, would also be highly relevant, even if
they are not yet currently used in clinical practice. If these
markers predict poor HPA function, one could predict that
treatments targeting the HPA axis (CRF1 antagonists, V1b
receptor antagonists, GR antagonists, FRBP51 inhibitors) could
be useful therapeutic strategies to improve drug response as
well as the onset of response when combined with more
conventional ADs.
Thyrotropin releasing hormone (TRH)
The relationship between thyroid function and MDD is well-
known. Indeed, hypothyroidism is associated with MDD, and
TRH levels correlate with symptom severity (Bauer et al., 2009).
Furthermore, MDD patients exhibit alterations in several mark-
ers of thyroid function, particularly of the thyroid hormone
triiodothyronine (T3) (see Hage and Azar, 2012 for a review).
Interestingly, T3 is widely used to improve the therapeutic out-
come of AD drugs in patients who exhibit poor response to
treatment (Aronson et al., 1996; Nierenberg et al., 2006), partic-
ularly in those treated with TCAs. Successful treatment with T3
alone has also been reported in some older studies (Feldmesser-
Reiss, 1958; Flach et al., 1958; Wilson et al., 1974). These findings
are further supported by preclinical evidence. Indeed, T3 alone
elicited an AD-like effect in a bio-assay for AD response (Lifschytz
et al., 2006, 2011), whereas the combination of T3 with chronic
fluoxetine increased the effects of the SSRI (Brochet et al., 1987;
Eitan et al., 2010). This effect appears to be related to thy-
roid function because it has also been shown that the effects of
TCAs are reduced in rats in which hypothyroidism has been pro-
voked by the addition of propylthiouracil to their drinking water
(Martin et al., 1987). The effects of T3 occur via an interaction
with nuclear thyroid hormone receptors (TRs). Four such recep-
tors have been described: α-1, α-2, β-1, and β-2. It would be of
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interest to determine which of these receptors might mediate the
effects of T3. A recent study demonstrated that administration
of dronedarone, a specific TRα antagonist, prevented the AD-like
effects of T3, suggesting that the TRα receptor is responsible for
the effects of T3 (Lifschytz et al., 2011). This observation is con-
sistent with the finding that TRα receptors are the most highly
expressed TRs in the brain (Williams, 2008) as well as with the
observation that mice in which this receptor is mutated display
depressive-like behavior (Pilhatsch et al., 2010).
Few studies have investigated the association of polymor-
phisms of thyroid function-related genes with MDD and AD
response. However, the relationship of a polymorphism of the
deiodinase type I (D1) gene (D1 converts inactive T4 to active
T3) with the ability of T3 to augment the effects of AD has been
investigated (Papakostas et al., 2009).
Interestingly, the effects of T3 in patients undergoing AD ther-
apy are particularly remarkable in some subcategories of patients,
particularly in women (Altshuler et al., 2001; Agid and Lerer,
2003) and in patients with atypical MDD.
Further progress could certainly be achieved in improving AD
response by (a) dosing pre-treatment T3 hormones in patients
and (b) studying polymorphisms of thyroid function related
genes. Such studies would enable the segregation of patients
according to their thyroid hormone status and the initiation of co-
therapy with T3 at the beginning of AD therapy in those patients
with the highest thyroid dysfunction.
DISCUSSION
To summarize, we know from various evidence from the lit-
terature that response to ADs can be driven but also altered
at various levels (Table 1). Derived from these data, several
peripheral or central biomarkers can now enable predicting an
increased risk of non-response to AD treatment. They include
markers genetic testing (polymorphisms of P450, ABCB1, SERT,
NERT, COMT, MAOA, leptin, FKBP5, hsp70, GR, BclI, CRHR1,
CRHR2, BDBF, D1, TRα genes, etc), plasmatic dosage (BDNF,
cortisol, FKBP51, etc.) or brain imaging. Predictors of treat-
ment response can easily be uncovered by deduction from
predictors of treatment non-response: for example, if a poor
response to ADs is met in Val allele carriers of the BDNF gene,
this also indicates that good response might be achieved in
the Met carriers. If poor response is shown in patients hav-
ing low rostral cingulate activity, high response is observed
in patients exhibiting elevated pretreatment rostral cingulate
activity.
Based on the potential mechanisms of response to AD, sev-
eral practical implications may be deducted (see Figure 1).
Some of these conclusions have entered clinical routine and
are now part of practical recommendations, such as augmenta-
tion therapy by thyroid hormones, and are sustained by strong
clinical evidence (Shelton et al., 2010). However, other innova-
tive strategies may enter further clinical investigation through
randomized controlled studies. Among these new strategies,
controlling co-medications, smoking status, or weight, assess-
ing pre-treatment hormonal status combined with dexametha-
sone/CRH tests and T3 levels, investigating SNPs of specific
genes known to be implicated in AD non-response, and the
use of brain imaging or EEG to identify brain changes known
to predict poor response to ADs are among the most promis-
ing. A more systematic referral to therapeutic drug monitoring
(plasma concentration quantification) would also be useful as it
appears to be largely insufficiently used given the considerable
inter-individual variability in the pharmacokinetic characteris-
tics of drugs. It enables the adaptation of the dosage of ADs to
achieve the plasma drug concentration that ensures the highest
probability of response (Hiemke et al., 2011). New augmenta-
tion strategies could also be developed based on the evidence
reported in the present review, such as combining monoamin-
ergic treatment with physical activity, cognitive training, stress
reduction, P-gp inhibitors, mu opioid receptors agonists, zinc,
and drugs targeting hormonal dysfunction (T3, FKBP5 inhibitor,
or CRH1 or V1b antagonists). Switching ADs from one ineffective
AD to a similar or different class of ADs and from SSRI/SNRIs
to TCAs, MAOIs, and non-conventional antidepressant drugs,
such as NMDA antagonists, may be other valuable strategies, as
well as switching to somatic therapies, such as ECT, rTMS, VNS,
or DBS.
One of the main obstacles to improving care strategies is the
wide heterogeneity of patients labeled as suffering from TRD
and/or showing insufficient response to conventional AD. This
heterogeneity is the consequence of the relatively poor speci-
ficity of the criteria for diagnosis, which are still based on clinical
evaluation; even the rating scales typically used to assess clinical
response exhibit relatively good inter-rater and test-retest valid-
ity. Moving toward a more systematic use of biomarkers may
improve the characterization of clinical phenotypes of MDD and
their biological, imaging or genetic, proteomic and metabolomic
correlates (Leuchter et al., 2010). As we have extensively reviewed,
although TRD and/or treatment non-response is a consider-
able challenge to improving patient outcome and preventing
severe complications of prolonged depressive states, it represents a
unique opportunity to better understand mechanism of action of
ADs and thus to better understand the pathophysiology of MDD
and improve its clinical characterization. This potential makes
research on TRD and/or treatment non-response a high priority
for new research developments at both the preclinical and clinical
levels.
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